AGFA HealthCare
10.6.2024 12:02:44 CEST | ACCESS Newswire | Press release
MORTSEL, BELGIUM / ACCESSWIRE / June 10, 2024 / AGFA HealthCare is thrilled to announce a significant new deal with Alliance Medical to implement an advanced cloud-based solution across all of Alliance Medical's UK sites. Powered by the AGFA HealthCare Enterprise Imaging Platform, this state-of-the-art approach supports Alliance Medical UK's Future Unified Diagnostic Information System (FUDIS) project. This project aims to streamline the entire patient pathway, establishing a robust and lasting partnership between AGFA HealthCare and Alliance Medical.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.
Deployment of the solution will begin later in 2024, with a phased implementation approach to ensure a smooth and efficient transition of all imaging services across 120 sites for all of Alliance Medical's UK community diagnostic centres (CDCs), static imaging sites for PET-CT, MRI, CT and other imaging modalities and its extensive fleet of mobile, modular and relocatable units, delivering over 400,000 annual exams.
Efficiency gains, clinical effectiveness, and collaboration workflows
Alliance Medical has been a trusted partner to the NHS for 30 years, providing diagnostic imaging solutions to patients throughout the UK. This partnership with AGFA HealthCare will play a pivotal role in achieving the strategic vision for Alliance Medical's UK business to provide long-term, sustainable diagnostic imaging solutions on behalf of the NHS and other partners.
"The ground-breaking partnership between Alliance Medical and AGFA HealthCare will play a key role in enabling us to achieve our strategic vision, on behalf of our patients and stakeholders, and will support our commitment to integrating diagnostics into existing care pathways. AGFA HealthCare's solution really led from the front, and the digital ecosystem they brought together will deliver the experience, knowledge and innovation needed to create a complete cloud-based solution which covers the entire end-to-end patient pathway," says Pete Winchester, UK Managing Director at Alliance Medical.
"We are delighted to further strengthen our partnership with Alliance Medical Group and the relationship with Alliance Medical UK, which is an integral part of the health economy in the UK and beyond. Combining that bond with our close collaboration with our market-leading partners will enable us to jointly deliver a luminary solution that brings together each of our leading technologies: enterprise imaging, clinical decision support, complex workflow orchestration and advanced augmented intelligence. These will run through the heart of the solution to enable clinicians to deliver outcomes for patients and an exceptional user experience that is rich in efficiency gains," says Roberto Anello, Regional President for Northern Europe for AGFA HealthCare.
Transformative Technologies Delivering an Exceptional User Experience
- The solution includes the AGFA HealthCare Enterprise Imaging Platform, with Shared Workflow and the XERO® Exchange Network (XEN):
- Designed around scalability, connectivity and clinical collaboration, Enterprise Imaging enables near-real-time access to images and delivers powerful tools and features for diagnosis, collaboration, workflow and more. By facilitating "imaging without barriers," it supports patient and clinician work-life balance, as well as the balancing of radiologists' tasks and reporting workloads between different organisations.
- Fully embedded artificial intelligence and advanced visualisation tools for molecular imaging all support complex clinical workflows by providing a solution that is readily available regardless of location and time.
- The Enterprise Imaging Collaborator tool and the new Shared Workflow feature offer completely new ways of managing activity to match reporting capacity with demand, improve clinician collaboration through multi-author workflows, and align unified ‘specialist' Reporting Worklists with scarce reporting skills. The embedded XERO® application enables clinical teams to engage and share information. Enterprise Imaging is now entering the era of streaming clients capable of displaying large amounts of data in near real-time.
- AGFA HealthCare Enterprise Imaging is powered by Amazon Web Services (AWS) cloud services, which gives Alliance Medical access to the security, reliability and scalability of the public cloud.
The platform is complemented for referrals by two market-leading solutions, including:
- xWave Technologies' Smart Referring, an advanced portal for referring clinicians, integrated with Enterprise Imaging XERO®. xWave Smart Referring incorporates a dynamic Clinical Decision Support system which supports clinicians in accessing the most appropriate diagnostic test for their patients. Innovations such as the Smart Vetting workflow also reduce workloads for administrative and clinical staff, while improving patient safety and care.
- Streets Heaver's Compucare® PAS/EPR (patient administration system/electronic patient record): This market-leading solution is designed for private patient workflows as well as managing NHS contracts and eReferrals. It supports all clinical activity types from general clinic consultations to diagnostic imaging workflows, as well as other non-imaging diagnostic services. Patient engagement is supported through the Patient Portal.
About AGFA HealthCare
At AGFA HealthCare, we are transforming the delivery of care - supporting healthcare professionals across the globe with secure, effective, and sustainable imaging data management. As a company, we are dedicated to our customers, and we have harnessed a value framework of Mission, Vision, and Customer Delivery Principles into our routine operations. Through these principles, we commit a consistent high-yield code of conduct to our associates - channelling our experience and aspirations to all our stakeholders. Our Empowerer profile supports our focus on creating an exceptional experience through the power of technology and is an integral foundation of our company standards. AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.com and follow us on LinkedIn.
AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. XERO® is a registered trademark of AGFA HealthCare N.V. All rights reserved. Compucare is a registered trademark of Streets Heaver Computer Systems Ltd. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.
Contact Information
Buse Kayar
buse.kayar@issuerdirect.com
SOURCE: AGFA HealthCare
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in
CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
